Joseph Catanzaro
Stock Analyst at Piper Sandler
(0)
# 4609
Out of 5,240 analysts
112
Total ratings
27.63%
Success rate
-17.29%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Exelixis | Maintains: Overweight | 36 37 | 36.33 | 1.84% | 3 | Jan 13, 2025 | |
Halozyme Therapeutic... | Maintains: Neutral | 52 53 | 54.57 | -2.88% | 8 | Jan 10, 2025 | |
Cardiff Oncology | Maintains: Overweight | 7 10 | 3.41 | 193.26% | 4 | Dec 13, 2024 | |
Revolution Medicines | Maintains: Overweight | 57 70 | 40.27 | 73.83% | 2 | Nov 7, 2024 | |
Gilead Sciences | Maintains: Overweight | 95 105 | 91.91 | 14.24% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 2 | 1.8 | 11.11% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 19 | 4.2 | 352.38% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 19 | 6 | 216.67% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 15 | 2.14 | 600.93% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 5 2 | 3.06 | -42.81% | 3 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 4 | 0.44 | 752.27% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 5 | 2.42 | 96.28% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 36 | 23.23 | 54.97% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 19 10 | 5.97 | 67.5% | 8 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 40 | 11.54 | 246.62% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 15 | 8.2 | 82.93% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 35 35 | 19.73 | 77.39% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 3 4 | 0.84 | 316.67% | 3 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 5 | 1 | 350% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 30 | 5.67 | 429.1% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 2.49 | 703.21% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 8 2 | 1.16 | 72.41% | 3 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 | 10.42 | 907.68% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 10 | 1.06 | 843.4% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 50 | 19.82 | 152.27% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | 2.75 | 554.55% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 10 | n/a | n/a | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 24 31 | n/a | n/a | 2 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 25 | 1.3 | 1823.08% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 58 | n/a | n/a | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 2 | 4.33 | -59.58% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 20 | 22.19 | -9.87% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 11 | n/a | n/a | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 90 70 | n/a | n/a | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 2 | 1.02 | 47.06% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 10 | 0.47 | 2027.66% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 600 500 | n/a | n/a | 1 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 35 | 5.93 | 490.22% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 60 | 2.58 | 2225.58% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 175 170 | n/a | n/a | 5 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 55 60 | n/a | n/a | 3 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | n/a | n/a | 2 | Jul 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 18 | 3.76 | 378.72% | 3 | Apr 7, 2020 |